Charts

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 56.0% to $0.81 during Wednesday's after-market session. Today's trading ...

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock increased by 30.1% to $33.8 during Monday's pre-market session. The company's market ...

Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file ...

Gainers Biocept (NASDAQ:BIOC) stock moved upwards by 48.9% to $0.76 during Wednesday's pre-market session. The company's market cap ...

Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a

Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 1642.4% to $4.18 during Wednesday's regular session. The current volume of 141.8 ...

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating ...

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired ...

Gainers Femasys (NASDAQ:FEMY) stock increased by 104.9% to $3.12 during Friday's regular session. Trading volume for Femasys's stock is ...

Gainers OpGen (NASDAQ:OPGN) shares increased by 128.9% to $0.46 during Friday's pre-market session. The company's market cap stands at ...

Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading. Novo Integrated Sciences, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news traders need to know about on Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Thursday. The Dow traded up 0.40% ...

Gainers Bionomics (NASDAQ:BNOX) stock increased by 261.4% to $3.56 during Thursday's regular session. As of 13:30 EST, Bionomics's ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although Baudax Bio saw significant interest because of its orphan drug designation, BXRX stock must climb a wall of worry. The post Why Is Baudax Bio (BXRX) Stock Up 75% Today? appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining 1% on Thursday. The Dow traded up 0.58% to ...

U.S. stocks traded higher this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening ...

Gainers Bionomics (NASDAQ:BNOX) shares increased by 579.2% to $6.69 during Thursday's pre-market session. The company's market cap ...

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the tre

Gainers Regulus Therapeutics (NASDAQ:RGLS) stock increased by 12.4% to $1.45 during Thursday's after-market session. The company's ...

MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be he

MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par

MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T c

Gainers NuCana (NASDAQ:NCNA) stock rose 17.3% to $0.84 during Friday's after-market session. This security traded at a volume of 164.1K ...

Gainers Nymox Pharmaceutical (NASDAQ:NYMX) stock moved upwards by 31.7% to $0.25 during Tuesday's regular session. Trading volume for ...

Gainers SQZ Biotechnologies (NYSE:SQZ) shares increased by 68.1% to $0.45 during Monday's regular session. The current volume of 30.0 ...

Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently ...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Friday. The Dow traded up 0.93% ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although Baudax Bio soared on Friday following its acquisition of Teralmmune, BXRX stock remains an extremely speculative venture. The post Why Is Baudax Bio (BXRX) Stock Up 130% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.

Baudax Bio Inc(NASDAQ: BXRX) shares are surging after the company announced the acquisition of TeraImmune, a privately held ...

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% ...

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology co

Baudax Bio Inc(NASDAQ: BXRX) announced additional results from its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in ...

Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Additional analy

Annual Meeting to be reconvened on June 23, 2023MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the “Annual Meeting”) without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company ...

Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

Baudax Bio (NASDAQ:BXRX) reported its Q1 earnings results on Friday, May 12, 2023 at 08:32 AM. Here's what investors need to know about ...

Table 1 FDA Required Primary Efficacy Endpoint Figure 2 Study BDX-22-006 Primary Endpoint Figure 3 Study BDX-22-006 Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4 Million in Gross Proceeds from Public Offering in May MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical compan

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.

MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place May 10-11, 2023. The presentation will begin at Wednesday, May 10 at 1:45pm, and can be accessed live here.

MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public offering of an aggregate of 3,478,262 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share (or pre-funded warrant

U.S. stocks extended gains toward the end of trading, with the Dow Jones gaining more than 500 points on Thursday. The Dow traded up ...

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday. The Dow traded ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Southwest Airlines (LUV) stock is taking a beating on Thursday after the travel company revealed results for the first quarter of 2023. The post Why Is Southwest Airlines (LUV) Stock Falling Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Meta Platforms (META) stock is gaining on Thursday after the social media company released its earnings report for the first quarter of 2023. The post Why Is Meta Platforms (META) Stock Up 15% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Impinj (PI) stock is falling on Thursday after the radio-frequency chipmaker released its earnings report for the first quarter of 2023. The post Why Is Impinj (PI) Stock Down 25% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Baudax Bio (BXRX) stock is falling hard on Thursday after the pharmaceutical company announced a $4 million public stock offering. The post Why Is Baudax Bio (BXRX) Stock Down 52% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) gained 115.4% to $0.2154 in pre-market trading. Evelo Biosciences shares dropped ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biggest pre-market stock movers are ready to go as we dive into the latest news traders need to know about on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the pricing of its public offering of an aggregate of 3,478,262 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share (or pre-funded warrant) and accompanying

All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to be Discussed in Key Opinion Leader Webinar Today at 10:00am Eastern Time MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade